Microbot Medical Secures Funding for Future Developments
Microbot Medical Inc. (NASDAQ: MBOT), a pioneering med-tech enterprise, has successfully raised approximately $11.8 million in gross proceeds through its recent funding initiatives. This impressive capital injection stems from a registered direct offering of 4,000,001 shares of common stock, priced at $1.75 each, under the current Nasdaq regulations. Alongside this, the company also conducted a concurrent private placement of short-term series G preferred investment options, vital for supporting its growth strategy.
Details of the Offering
This funding initiative involved H.C. Wainwright & Co. serving as the sole placement agent. The anticipated gross proceeds generated approximately $7 million from the registered direct offering, before factoring in agent fees and other related expenses. Furthermore, the company has previously raised about $4.8 million through its ongoing at-the-market facility.
Utilization of Funds
Microbot Medical plans to allocate the net proceeds from this funding towards advancing its innovative LIBERTY® Robotic System, an advanced endovascular robot designed for enhanced surgical precision. These funds will also support the development of additional applications from the company’s extensive intellectual property portfolio, alongside necessary working capital for operational purposes.
Regulatory Considerations
The shares issued were made under an effective shelf registration statement filed with the Securities and Exchange Commission (SEC), ensuring compliance with legal requirements. The LIBERTY® Robotic System has been crucial for the company's vision, allowing enhanced access to advanced medical procedures for healthcare providers and patients alike.
About Microbot Medical Inc.
Founded with the mission to revolutionize patient care, Microbot Medical Inc. focuses on developing transformative technology to improve healthcare delivery. Their flagship ROBOTIC SYSTEM stands out as the world’s first fully disposable device, aimed at breaking down existing barriers in robotic-assisted surgeries, thereby facilitating more accessible and efficient treatment options.
Company Growth and Future Outlook
The investment opportunities and progress realized from the latest funding round signify a robust commitment toward Microbot Medical’s operational advancements. The company is actively pursuing further developments aimed at commercializing the LIBERTY® Robotic System, ensuring it meets the necessary regulatory requirements for market entry.
Advantages of the New System
The single-use nature of the LIBERTY® system not only enhances infection control measures but also reduces costs associated with traditional robotic systems. This innovation is set to significantly benefit health professionals and increase the accessibility of advanced medical technology.
Frequently Asked Questions
What is the purpose of the recent funding raised by Microbot Medical?
The funding is aimed at advancing the development and commercialization of the LIBERTY® Robotic System and expanding additional applications from its IP portfolio.
Who acted as the placement agent for Microbot Medical's offerings?
H.C. Wainwright & Co. served as the exclusive placement agent for Microbot Medical's recent funding initiatives.
How much total capital has Microbot Medical raised recently?
The total gross proceeds raised amount to approximately $11.8 million, combining funds from the registered direct offering and previous at-the-market facilities.
What are the expected benefits of the LIBERTY® Robotic System?
The LIBERTY® Robotic System aims to enhance surgical precision and accessibility while reducing hospital costs and improving patient outcomes.
Where can I find more information about Microbot Medical?
To learn more about Microbot Medical Inc., visit their official website at www.microbotmedical.com.
